ArticleImmunity2010
Act1, scene brain: astrocytes play a lead role.
Article in Immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- EZH2 Mediates miR-146a-5p/HIF-1Mediators of inflammation · 2021Article
- Maternal IL-17A in autism.Experimental neurology · 2018Review
- Lumican negatively controls the pathogenicity of murine encephalitic TH17 cells.European journal of immunology · 2016Article
- Control of IL-17 receptor signaling and tissue inflammation by the p38α-MKP-1 signaling axis in a mouse model of multiple sclerosis.Science signaling · 2015Article
- IL-17A induces MIP-1α expression in primary astrocytes via Src/MAPK/PI3K/NF-kB pathways: implications for multiple sclerosis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2014Article
- The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis.Sultan Qaboos University medical journal · 2014Review
- TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development.Immunogenetics · 2013Article
- What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?International journal of molecular sciences · 2012Review
- A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Discovery medicine · 2011Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
Interleukin-17 (IL-17) is crucial for the progression of experimental autoimmune encephalomyelitis. In this issue of Immunity, Kang et al. (2010) report that neuroectoderm-derived astrocytes are the critical cellular element that responds to IL-17.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.